It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Alkyl isonitriles, R—NC, have previously been shown to ligate the heme (haem) iron of cytochromes P450 in both accessible oxidation states (ferrous, Fe2+, and ferric, Fe3+). Herein, the preparation of four steroid-derived isonitriles and their interactions with several P450s, including the steroidogenic CYP17A1 and CYP106A2, as well as the more promiscuous drug metabolizers CYP3A4 and CYP2D6, is described. It was found that successful ligation of the heme iron by the isonitrile functionality for a given P450 depends on both the position and stereochemistry of the isonitrile on the steroid skeleton. Spectral studies indicate that isonitrile ligation of the ferric heme is stable upon reduction to the ferrous form, with reoxidation resulting in the original complex. A crystallographic structure of CYP17A1 with an isonitrile derived from pregnanalone further confirmed the interaction and identified the absolute stereochemistry of the bound species.
all
The inhibition of cytochrome P450 (CYP) enzymes is central to many therapeutics, however, achieving selectivity across CYP enzymes remains challenging. Here, the authors develop isonitrile-harboring steroids as selective steroidogenic CYP heme iron ligands.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 University of Michigan, Chemical Biology Program, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000 0004 1936 7347)
2 Brandeis University, Dept. of Biochemistry, Waltham, USA (GRID:grid.253264.4) (ISNI:0000 0004 1936 9473)
3 University of Michigan, Department of Medicinal Chemistry, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000 0004 1936 7347)
4 University of Michigan, Chemical Biology Program, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000 0004 1936 7347); University of Michigan, Department of Medicinal Chemistry, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000 0004 1936 7347); University of Michigan, Departments of Pharmacology and Biological Chemistry, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000 0004 1936 7347)
5 Brandeis University, Dept. of Biochemistry, Waltham, USA (GRID:grid.253264.4) (ISNI:0000 0004 1936 9473); Brandeis University, Dept. of Chemistry and Rosenstiel Basic Medical Sciences Research Center, Waltham, USA (GRID:grid.253264.4) (ISNI:0000 0004 1936 9473)